# Daniel Getts

> Daniel Getts, PhD, is the co-founder and CEO of CREATE Medicines (formerly Myeloid Therapeutics), a Cambridge, Massachusetts biotech building RNA-based in vivo immune programming therapies that reprogram T cells, NK cells and myeloid cells directly inside the body. An immunologist trained at the University of Sydney with an MBA from Western Michigan, he previously founded Cour Pharmaceuticals and served as VP of Research at TCR2 Therapeutics. He has more than 45 peer-reviewed publications, multiple issued patents, and a track record of large pharma partnerships, including Takeda's $420M licensing deal for TIMP-GLIA. In May 2026 CREATE closed a $122 million Series B to advance its in vivo CAR pipeline across autoimmune disease and oncology.

- **Role:** Chief Executive Officer & Co-Founder at CREATE Medicines
- **Organizations:** CREATE Medicines, Myeloid Therapeutics, Cour Pharmaceuticals, TCR2 Therapeutics, Tolera Therapeutics, Curate Biosciences, Northwestern University
- **Nationality:** Australian
- **Education:** PhD in Medicine (Immunology), University of Sydney, MBA, Western Michigan University, Postdoctoral Fellowship (lab of Stephen D. Miller), Northwestern University
- **Known for:** Co-founded and leads CREATE Medicines (formerly Myeloid Therapeutics), a clinical-stage RNA immunotherapy company, Primary inventor and founder of Cour Pharmaceuticals; its TIMP-GLIA platform was licensed to Takeda for $420M plus royalties, Helped guide TCR2 Therapeutics through a $120M Series B and an IPO as VP of Research

## Career timeline

- **2008** — Submitted PhD in Medicine at the University of Sydney
- **2009** — Completed postdoctoral fellowship at Northwestern University under Stephen D. Miller
- **2010s** — Director of R&D at Tolera Therapeutics, advancing a monoclonal T-cell antibody program from discovery toward Phase 3
- **2012** — Founded Cour Pharmaceuticals as primary inventor and Chief Scientific Officer, later licensing TIMP-GLIA to Takeda for $420M plus royalties
- **2018** — Joined TCR2 Therapeutics as VP of Research, helping lead a $120M Series B and roughly $80M IPO
- **2019** — Co-founded Myeloid Therapeutics, serving as CEO
- **2022** — Appointed to the Board of Directors of Curate Biosciences
- **2025** — Rebranded Myeloid Therapeutics as CREATE Medicines, expanding to multilineage in vivo immune programming
- **2026** — Announced $122 million Series B to advance in vivo CAR pipeline across autoimmune disease and oncology

## Achievements

- Co-founded and leads CREATE Medicines (formerly Myeloid Therapeutics), a clinical-stage RNA immunotherapy company
- Primary inventor and founder of Cour Pharmaceuticals; its TIMP-GLIA platform was licensed to Takeda for $420M plus royalties
- Helped guide TCR2 Therapeutics through a $120M Series B and an IPO as VP of Research
- Author of more than 45 peer-reviewed publications, including in Nature Biotechnology, Science Translational Medicine and Nature Communications
- Holds more than 10 issued patents with many pending
- Oversaw clinical dosing of MT-302, a TROP2-targeting in vivo RNA CAR, in a Phase 1 study
- Companies have collectively advanced multiple novel therapies into clinical trials across cancer, autoimmune disease and transplant rejection

## Latest updates

- **2026-05** — CREATE Medicines announced a $122 million Series B financing to advance its in vivo CAR pipeline in autoimmune disease and oncology.
- **2025** — Myeloid Therapeutics rebranded as CREATE Medicines, expanding from myeloid-focused to multilineage in vivo immune programming of T cells, NK cells and myeloid cells.

## Links

- Website: https://createmedicines.com
- LinkedIn: https://www.linkedin.com/in/danielgetts/
- Twitter/X: https://twitter.com/MyeloidTx

---

Profile page: https://yespress.io/daniel-getts
Published by YesPress — https://yespress.io
Last updated: 2026-07-22